Cycloastragenol (TA-65)

Cycloastragenol is a lanostane-type pentacyclic triterpene aglycone derived from the roots of Astragalus membranaceus and Astragalus mongholicus, plants with over 2,000 years of use in Traditional Chinese Medicine as tonics for immune function, stamina, and longevity. The compound is the aglycone form of astragaloside IV, meaning it is astragaloside IV with its glucose sugar groups removed, and this structural change dramatically improves its membrane permeability and oral bioavailability compared to the parent glycoside. Cycloastragenol was identified through proprietary high-throughput cell-based screening by T.A. Sciences as the specific constituent of Astragalus root responsible for the telomerase-activating activity observed in bioassay-guided fractionation studies, and was subsequently developed as the active ingredient in the TA-65 supplement. The commercial TA-65 preparations standardized to cycloastragenol content represent the most studied and characterized form, with multiple peer-reviewed human clinical publications, distinguishing cycloastragenol from the broader category of astragaloside supplements that do not contain telomerase-active concentrations of the purified compound.

Telomerase is the ribonucleoprotein enzyme responsible for maintaining telomere length during cell division. It consists of two core components: TERT (telomerase reverse transcriptase), the catalytic protein subunit that synthesizes telomere repeats (TTAGGG)n using its own RNA template, and TERC (telomerase RNA component), which provides the RNA template sequence. In most somatic cells after differentiation, TERT expression is silenced through epigenetic mechanisms including promoter CpG methylation and histone modifications, leaving telomeres to shorten progressively with each cell division. When critically short telomeres accumulate, they trigger the ATM/ATR DNA damage response at chromosome ends, activating p53 and p21 to drive cells into irreversible senescence or apoptosis. This telomere-driven senescence accumulates across tissues over decades, contributing to age-related tissue dysfunction, chronic inflammation (through the SASP of senescent cells), and reduced regenerative capacity. Cycloastragenol partially reverses the epigenetic silencing of TERT in somatic cells that have short telomeres, transiently increasing telomerase activity and allowing extension of the shortest telomeres in the cell population.

The molecular mechanism of TERT activation by cycloastragenol involves interactions with transcription factors at the TERT promoter. TERT promoter activity is regulated by a complex network including activating factors (c-Myc, SP1, NF-kappaB in some contexts) and repressors (p53, WT1, E2F1). Cycloastragenol increases TERT mRNA and protein in short-telomere and aging cells through a mechanism that appears to involve NF-kappaB pathway modulation: while cycloastragenol suppresses the classical pro-inflammatory NF-kappaB activation that drives cytokine expression, it may selectively influence the non-canonical NF-kappaB pathway (RelB, p52) that is one of the transcriptional activators of the TERT promoter. Additionally, cycloastragenol may influence the Wnt/beta-catenin pathway, which is a direct TERT transcriptional activator through TCF/LEF binding sites in the TERT promoter. These mechanisms explain the cell-state-specific and dose-dependent nature of cycloastragenol TERT activation: the compound preferentially activates TERT in cells with short telomeres or quiescent stem cells rather than uniformly in all cells, which is considered the desirable activation profile for a longevity intervention.

The clinical evidence base for cycloastragenol is more limited than for established longevity supplements like resveratrol or berberine, but is notable for directly measuring the proposed molecular target (telomere length) rather than relying solely on surrogate biomarkers. The 2011 Harley et al. open-label study, published in Rejuvenation Research, provided the first human evidence of oral small-molecule telomere elongation, finding significant reductions in the proportion of short telomeres in white blood cells and improvements in CMV-associated immune senescence markers. The 2013 Fernandez et al. randomized double-blind trial in HIV patients confirmed these immune telomere findings with higher methodological rigor. These findings are particularly compelling because telomere length is not easily confounded by placebo effects (being measured by quantitative PCR or flow cytometry). However, the translation of telomere length changes to clinical outcomes (disease prevention, lifespan extension) has not been demonstrated, and the cancer safety question over decades of use remains the dominant uncertainty for cycloastragenol as a longevity intervention.

Mechanism of Action

TERT Promoter De-repression and Telomerase Activation

Telomerase is the enzyme that extends telomeres by adding TTAGGG hexanucleotide repeats to chromosome ends. The catalytic subunit TERT is expressed at negligible levels in most somatic cells after differentiation because the TERT promoter undergoes progressive epigenetic silencing including CpG methylation and repressive histone modifications (H3K9me3, H3K27me3). This silencing is maintained by repressor complexes including p53/Sp3 and E2F/Rb that bind to repressor elements in the TERT promoter, preventing productive TERT transcription even when the gene is structurally intact.

Cycloastragenol reverses this silencing through multiple mechanisms. It activates the Wnt/beta-catenin signaling pathway: when cycloastragenol stabilizes beta-catenin from GSK3beta-mediated phosphorylation and degradation, free beta-catenin translocates to the nucleus where it forms a complex with TCF/LEF transcription factors that bind to beta-catenin response elements (CREs) in the TERT promoter, driving TERT transcription. The TERT promoter contains at least two functional CRE/TCF binding sites that mediate this Wnt-dependent activation. Additionally, cycloastragenol modulates NF-kappaB signaling in a context-dependent manner: while suppressing the classical NF-kappaB pathway (p65/RelA-dependent, pro-inflammatory), it may activate the non-canonical NF-kappaB pathway (RelB/p52-dependent), which has independent TERT promoter transactivation activity through NF-kappaB binding sites identified in the proximal TERT promoter region.

The net result of cycloastragenol treatment in short-telomere cells is a 2 to 4 fold increase in TERT mRNA, increased telomerase enzyme activity (measured by the TRAP assay), and preferential elongation of the shortest telomeres in the cell population. The short-telomere preference arises because very short telomeres are more accessible to telomerase (being less compacted by shelterin proteins) and because the ATR-dependent DNA damage signaling at very short telomeres actually recruits telomerase to these locations.

Telomere Length Restoration and DNA Damage Response Suppression

Critically short telomeres (below 4 to 5 kb) are recognized by the p53 pathway as double-strand breaks because the T-loop structure cannot form when telomeres are too short to provide a sufficient ssDNA overhang. This activates ATM/ATR kinase signaling, which phosphorylates H2AX (gamma-H2AX), recruits 53BP1, and ultimately activates p53 to enforce the p21-dependent cell cycle arrest that drives cells into senescence. By elongating these critically short telomeres above the threshold at which the DNA damage signal is triggered, cycloastragenol reduces the number of gamma-H2AX foci and 53BP1 recruitment events in aging cell populations, suppresses p53 activation and p21 induction, and allows cells that were at the threshold of senescence to re-enter the cell cycle.

This reversal of telomere-driven senescence is considered biologically meaningful because it is distinct from simply suppressing the p53 pathway (which would allow genetically damaged cells to continue dividing): instead, it removes the upstream signal (critically short telomeres) that was legitimately activating the DNA damage response, achieving a correction rather than an override.

Mitochondrial TERT and Non-Telomeric Functions

TERT is not exclusively a nuclear telomere maintenance enzyme. Under conditions of mitochondrial oxidative stress, TERT translocates from the nucleus to mitochondria, where it associates with mitochondrial DNA and mitochondrial RNA processing enzymes. Mitochondrial TERT reduces mitochondrial ROS production, decreases mitochondrial DNA damage, and reduces cytochrome c release that would otherwise trigger the intrinsic apoptosis pathway. Cycloastragenol-induced TERT expression increases both the nuclear pool available for telomere maintenance and the mitochondrial pool available for mitochondrial protection, providing a dual mechanism for cellular protection from both replicative senescence (nuclear) and oxidative damage (mitochondrial).

TERT also has direct extra-telomeric transcriptional functions, acting as a co-activator of Wnt/beta-catenin target genes and as a component of chromatin remodeling complexes. These non-telomeric TERT functions contribute to the maintenance of stem cell self-renewal capacity, neural progenitor proliferation, and hair follicle cycling, and may explain why TERT activation has broader regenerative effects than would be predicted from telomere length changes alone.

NF-kappaB Suppression and Anti-Inflammatory Mechanism

Cycloastragenol suppresses classical NF-kappaB activation through direct inhibition of IKK-beta kinase activity. IKK-beta phosphorylates IkappaB-alpha at Ser32 and Ser36, leading to IkappaB-alpha ubiquitination and proteasomal degradation, which releases p65/p50 NF-kappaB dimers to translocate to the nucleus and drive inflammatory gene transcription. Cycloastragenol prevents IkappaB-alpha phosphorylation, trapping NF-kappaB in the inactive cytoplasmic complex and reducing transcription of TNF-alpha, IL-6, IL-1beta, MCP-1, and ICAM-1. This anti-inflammatory activity is relevant not only as a direct health benefit but also as a mechanism supporting TERT activation, since NF-kappaB (specifically p65) is a transcriptional repressor of TERT in differentiated cells, meaning that NF-kappaB suppression reduces one of the key barriers to TERT promoter activation.

Epigenetic Modulation

The primary epigenetic mechanism of cycloastragenol is the reversal of TERT promoter silencing, which is itself an epigenetic phenomenon. The TERT promoter in differentiated somatic cells carries repressive marks including high CpG methylation density, reduced H3K4me3 (active mark) and increased H3K27me3 and H3K9me3 (repressive marks). Cycloastragenol-driven Wnt/beta-catenin activation recruits TCF/LEF complexes that associate with CBP/p300 histone acetyltransferases at the TERT promoter, introducing H3K27ac marks that convert the promoter from the repressed to the poised or active state.

Additionally, SIRT6 (which cyanidin and other compounds activate) controls H3K9 acetylation at telomeric chromatin, and telomere chromatin composition influences how accessible telomeres are to telomerase. When telomeric histones are inappropriately acetylated, telomere elongation by telomerase is impaired even when the enzyme is active. Optimal telomere maintenance therefore requires both adequate telomerase activity (supported by cycloastragenol) and appropriate telomeric chromatin structure (supported by SIRT6 activity through NAD+-dependent deacetylation). This mechanistic connection explains why combining cycloastragenol with NAD+ precursors and SIRT6 activators may provide greater telomere maintenance benefits than cycloastragenol alone.

Clinical Evidence

Human Telomere Elongation: Open-Label Evidence

The 2011 Harley et al. study published in Rejuvenation Research provided the first published evidence that an oral small molecule could elongate human telomeres in vivo. Participants were 114 relatively healthy adults with a mean age of approximately 60 years who chose to purchase and take TA-65 as part of a health maintenance program. After 1 year, the proportion of critically short telomeres (below 4 kb) in CD4+ and CD8+ T cells was significantly lower in TA-65 users compared to an age-matched reference cohort from the same physician practice who chose not to use the supplement. Additionally, the TA-65 group showed significant improvements in CMV-associated immune senescence markers, including reduced CD28-null T cell percentage. The authors acknowledged the observational design as a limitation and noted that selection bias (healthier, more motivated participants choosing supplementation) could not be excluded.

Randomized Trial in HIV-Positive Patients

The 2013 Fernandez et al. randomized double-blind placebo-controlled trial enrolled 97 HIV-positive adults on stable antiretroviral therapy. HIV-positive individuals have accelerated immune aging with shortened T cell telomeres and expanded CD28-null T cell populations due to chronic immune activation and viral load effects. After 12 months of supplementation, the cycloastragenol group showed significantly reduced percentage of short telomeres in both CD4+ and CD8+ T cells, significantly improved CD4+/CD8+ ratio, and significantly reduced the proportion of senescent CD28-null T cells, compared to placebo. This study is considered the most rigorous published evidence for cycloastragenol immune telomere effects due to its randomized, controlled, blinded design with objective telomere measurement endpoints.

Cardiovascular Patients with Short Telomeres

The 2016 Salvador et al. study examined TA-65 supplementation in cardiovascular disease patients who had short telomeres at baseline, identified as a high-risk subgroup. After supplementation, significant reductions in the proportion of short telomeres were observed, with the magnitude of telomere elongation response inversely correlated with baseline telomere length: patients with the shortest baseline telomeres showed the greatest elongation. This dose-response relationship between baseline telomere length and response magnitude is consistent with the short-telomere-preferential activation model and suggests that the intervention may be most clinically meaningful in populations with accelerated telomere shortening.

Cancer Safety Evidence

No published clinical study of cycloastragenol has reported an increase in cancer incidence compared to control groups. The Harley et al. open-label study specifically reported no excess cancer events after 1 year. However, it is important to acknowledge that all published human cycloastragenol studies have been short (1 to 2 years), small (fewer than 300 participants), and not powered to detect moderate increases in cancer incidence. The latency period between cancer initiation and clinical detection can be decades, meaning that even a 2-year study with impeccable design could not rule out a meaningful increase in cancer risk over a 10 to 20 year supplementation period. This uncertainty is the defining limitation of cycloastragenol as a longevity intervention and is not a reflection of any identified safety signal in the published data.

Dosing Guidance

Based on published clinical protocols, the most evidence-supported regimen for telomere maintenance is 10 to 25 mg cycloastragenol per day (equivalent to approximately 500 to 1,000 TA-65 units) taken with a fat-containing meal for at least 12 months. Shorter durations appear insufficient for meaningful telomere length changes based on the kinetics observed in clinical studies. Lower doses of 5 to 10 mg per day may be appropriate for maintenance after an initial higher-dose induction phase, or for younger adults using cycloastragenol prophylactically. Cancer screening before initiation and periodic monitoring (annually) are strongly recommended. Combining with NAD+ precursors to support SIRT6 and PARP1 telomere maintenance activities is a mechanistically supported complement strategy. Baseline telomere length testing allows stratification of expected response: individuals with documented short telomeres are most likely to show measurable elongation responses.